DailyIQ
|
Sector:HealthcareAll sectors
Last updated 3 minutes ago

RHHBY·Roche Holding AG

$.
+. (+.%)
After Hours
High
$51.36
Open
$50.46
Market Cap
260.89B
52W High
$374.90
Low
$50.40
P. Close
$51.19
P/E
20.26
52W Low
$243.90
Fwd P/E
-
DailyIQ Est.
$57.04
Technical Score (1D)
55
BUY
News Sentiment
76
BULLISH
The FDA has granted priority review to Roche’s Gazyva/Gazyvaro for primary membranous nephropathy, a move that signals a potential first FDA‑approved therapy for the disease. This priority review follows phase III MAJESTY trial data showing higher complete remission rates versus tacrolimus, indicating a clinically meaningful advantage that could drive adoption. The accelerated review process means the drug could reach the market sooner, expanding RHHBY’s therapeutic portfolio and potentially increasing its market share in the nephrology space. A faster approval could also prompt Roche to launch the drug earlier, creating a competitive advantage over existing treatments and positioning RHHBY as a leader in this niche. Traders should monitor the FDA’s final approval timeline, as the exact date will determine when sales can begin and when the company can start generating revenue from the new indication. Post‑approval sales data will be critical to assess whether the higher remission rates translate into real‑world uptake and revenue growth for RHHBY. Reimbursement coverage decisions will also influence market penetration, so keeping an eye on payer negotiations and coverage determinations is essential. Additionally, watch for any updates on the drug’s safety profile or adverse event reports, which could affect its market acceptance and pricing strategy. Finally, observe competitor responses, such as potential new entrants or accelerated development of alternative therapies, as these could alter the competitive landscape and impact RHHBY’s valuation over the next 1–10 trading days.
Earnings Summary
Roche Holding AG, a global healthcare leader established in 1896 and headquartered in Basel, Switzerland, operates significantly within the pharmaceuticals and diagnostics sectors. The company focuses on developing innovative treatments for oncology, immunology, and neurological disorders, complemented by a robust diagnostics division that aids in disease detection and management. This integrated approach positions Roche strongly within the competitive healthcare industry. Roche's recent financial performance shows a mixed trend. In Q1 2026, the company reported revenue estimates of $15.735 billion, though actual results were not provided. Looking back, the most recent reported quarters indicate a deceleration in revenue growth compared to the prior two periods, though specific figures for EPS and revenue actuals are not available for direct comparison. Historically, Roche has demonstrated a strong revenue growth trajectory year-over-year, driven by its pharmaceutical segment, particularly oncology therapies from Genentech. While specific beat/miss patterns against analyst estimates for EPS and revenue are not detailed in the provided data, the company's pipeline advancements suggest continued potential. Recent news highlights significant developments, including the "All Eyes on DME" campaign by Genentech to raise awareness for diabetic macular edema, potentially boosting demand for related treatments. Furthermore, Roche's experimental multiple sclerosis drug, fenebrutinib, has shown promising relapse reduction in Phase III trials, though safety concerns related to reported deaths warrant close monitoring. Advancements in Gazyva's application for lupus erythematosus and Enspryng's efficacy in MOGAD trials also point to future growth drivers. Investors will be watching for the impact of the DME awareness campaign on sales and any further regulatory developments or clarifications regarding the safety profile of fenebrutinib. Key will be the company's ability to translate pipeline successes into market share and sustained revenue growth, particularly in its core therapeutic areas.

EPS

EstBeatMiss
No data available
QtrEstActual+/−
Q1'26 - - -

Revenue

EstBeatMiss
$15.7B$15.7B$15.7B$15.7B$15.7BQ1'26
QtrEstActual+/−
Q1'26$15.7B - -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

RHHBY Stock Snapshot

RHHBY is currently trading at $51.19, giving Roche Holding AG a market cap of 260.89B and a P/E ratio of 20.3. Today's range spans $50.40–$51.36, with shares opening at $50.46 and moving up $0.00 (0.0%) from the prior close. DailyIQ's technical score sits at 55/100 (HOLD) with a news sentiment reading of 76/100.

Over the past year RHHBY has traded between $243.90 and $374.90 - the current price is -79.0% off the 52-week low and -86.3% from the high. 28 analysts cover the stock with a Hold consensus and a mean 12-month target of $56.66 (range $46.00–$67.00), implying upside of +10.7%.

A HOLD read (55/100) for RHHBY at $51.19 (near 52-week lows) with bullish sentiment (76/100) tells the story of a large-cap Healthcare stock between identifiable trends. The current P/E ratio stands at 20.3. The 260.89B market cap keeps institutional interest alive; the 52-week range of $243.90–$374.90 keeps the trade interesting. HOLD signals here aren't an endpoint - they're a setup phase waiting for the right trigger.

The 52-week range of $243.90–$374.90 for RHHBY provides the structural reference that options traders, systematic funds, and discretionary managers all anchor to — and at $51.19 (near 52-week lows), the stock sits in a zone where the next 5–10% move will likely define which crowd was right. A HOLD signal at 55/100 and bullish news backdrop (76/100) don't break the tie yet, but they narrow the probability distribution toward the upside.